mRNA-4157,Pembrolizumab
Moderna,Merck
['melanoma', 'pembro']
adding an mrna vaccine to adjuvant treatment with pembrolizumab prolongs relapse-free survival in high-risk melanoma, a phase 2 study presented at aacr 2023 suggests. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.